Literature DB >> 2190685

Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Lipoprotein Conference Ad Hoc Committee on Guidelines for Dyslipoproteinemias.

.   

Abstract

Elevated plasma levels of cholesterol and triglycerides, low levels of high-density lipoproteins, hypertension, diabetes mellitus, smoking and abdominal obesity are risk factors for coronary heart disease (CHD) and stroke. Because of the preventable threat to life, well-being and productivity from perturbations of plasma lipoproteins (which affect about 60% of adults), we recommend a population-based strategy with public education on diet, exercise and the hazards of smoking and legislation for better food labelling. This should be combined with the medical guidelines we describe to detect and treat those at highest risk for CHD (including about 15% of adults), who merit priority for the medical, dietetic and laboratory services required. Among people aged 40 years or more this includes those with plasma total cholesterol levels greater than 7 mmol/L, fasting triglyceride levels greater than 3 mmol/L or cholesterol level greater than 6 mmol/L when associated with CHD or other risk factors for CHD. For younger people the criteria for highest risk include cholesterol levels greater than 6.5 mmol/L for those aged 30 to 39 years, greater than 6 mmol/L for those aged 20 to 29 and greater than 5 mmol/L for those under age 20.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190685      PMCID: PMC1451984     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  87 in total

1.  Is the ratio of apo B/apo A-I an early predictor of coronary atherosclerosis?

Authors:  W A Van Stiphout; A Hofman; H A Kruijssen; R Vermeeren; P H Groot
Journal:  Atherosclerosis       Date:  1986-11       Impact factor: 5.162

2.  Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.

Authors:  J Slack
Journal:  Lancet       Date:  1969-12-27       Impact factor: 79.321

3.  Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men.

Authors:  R M Krauss; F T Lindgren; P T Williams; S F Kelsey; J Brensike; K Vranizan; K M Detre; R I Levy
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

4.  Cholesterol and mortality. 30 years of follow-up from the Framingham study.

Authors:  K M Anderson; W P Castelli; D Levy
Journal:  JAMA       Date:  1987-04-24       Impact factor: 56.272

5.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

Authors:  D H Blankenhorn; S A Nessim; R L Johnson; M E Sanmarco; S P Azen; L Cashin-Hemphill
Journal:  JAMA       Date:  1987-06-19       Impact factor: 56.272

6.  Changes in serum lipoproteins and high-density lipoprotein composition during isotretinoin therapy.

Authors:  T J O'Leary; I E Simo; N Kanigsberg; J Walker; J C Goodall; T C Ooi
Journal:  Clin Invest Med       Date:  1987-07       Impact factor: 0.825

7.  Relation of parental history of early myocardial infarction to the level of apoprotein B in men.

Authors:  F Cambien; J M Warnet; A Jacqueson; P Ducimetiere; J L Richard; J R Claude
Journal:  Circulation       Date:  1987-08       Impact factor: 29.690

8.  Serum lipids after stroke.

Authors:  I Mendez; V Hachinski; B Wolfe
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

9.  Serum lipids and apolipoproteins in families of postinfarction men.

Authors:  A Jirkovská; J Válek; D Grafnetter; K Vondra; J Skibová
Journal:  Ann Clin Res       Date:  1987

10.  Efficacy of a continuous estrogen-progestin regimen in the menopausal patient.

Authors:  L Weinstein
Journal:  Obstet Gynecol       Date:  1987-06       Impact factor: 7.661

View more
  1 in total

1.  Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.

Authors:  Jianhua Wu; Shihua Zhu; Guiqing Lily Yao; Mohammed A Mohammed; Tom Marshall
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.